Dr. Martens plc (LON:DOCS – Get Free Report) insider Giles Wilson bought 237 shares of the company’s stock in a transaction that occurred on Wednesday, November 11th. The stock was purchased at an average cost of GBX 63 per share, for a total transaction of £149.31.
Dr. Martens Trading Down 18.3%
LON:DOCS opened at GBX 53.10 on Thursday. The company has a market cap of £508.31 million, a P/E ratio of 22.12, a price-to-earnings-growth ratio of 6.40 and a beta of 0.26. Dr. Martens plc has a twelve month low of GBX 52.10 and a twelve month high of GBX 90. The business has a 50 day moving average price of GBX 67.13 and a two-hundred day moving average price of GBX 69.53. The company has a quick ratio of 1.13, a current ratio of 2.61 and a debt-to-equity ratio of 108.85.
Dr. Martens (LON:DOCS – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported GBX (1) earnings per share (EPS) for the quarter. The business had revenue of £290.40 million during the quarter. Dr. Martens had a net margin of 3.11% and a return on equity of 6.89%. As a group, analysts expect that Dr. Martens plc will post 2.58 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Separately, Berenberg Bank reiterated a “buy” rating and issued a GBX 110 price target on shares of Dr. Martens in a research note on Friday, October 9th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 105.
Get Our Latest Analysis on Dr. Martens
About Dr. Martens
Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot – named after the date it was produced – rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, “Docs” or “DM’s” were later adopted by musicians and subcultural pioneers who took them from the street to the global stage. Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.
See Also
- Five stocks we like better than Dr. Martens
- The Post-Midterm Rally Clock Is Ticking—and These 3 AI Stocks Stand Out
- Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
- Palantir’s Real Washington Risk Isn’t the Budget—It’s Oversight
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
Receive News & Ratings for Dr. Martens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Martens and related companies with MarketBeat.com's FREE daily email newsletter.
